Beam Therapeutics reports Q4 2022 net loss of $38.3M; cash at $1.1B, runway into 2025

Beam Therapeutics Inc.

2022-FY EPS reported -$4.13 revenue$60,920,000

Net loss Q4 2022: $38.3M ($0.54/share) vs $64.7M ($0.95/share) in Q4 2021; full year net loss $289.1M ($4.13/share).
Cash, cash equivalents and marketable securities $1.1B as of Dec 31, 2022, up from $965.6M at Dec 31, 2021.
R&D expenses $86.3M in Q4 2022, down from $96.8M in Q4 2021; G&A expenses $22.7M vs $17.8M.
Pipeline milestones: BEAM-101 sentinel cohort enrollment to finish 2023, BEAM-201 first patient dosing by mid-2023, BEAM-301 and BEAM-302 regulatory filings in late 2023/early 2024.
North Carolina manufacturing facility expected to commence cGMP operations in late 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Beam Therapeutics Inc. reported the fourth quarter of 2022 results: net income Net loss attributable to common stockholders was $38.3 million, or $0.54 per share, for the fourth quarter of 2022, EPS $0.54 per share. Guidance reaffirmed.

Period: the fourth quarter of 2022
Net income: Net loss attributable to common stockholders was $38.3 million, or $0.54 per share, for the fourth quarter of 2022
EPS: $0.54 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

issued a press release announcing the Company’s financial results for the quarter ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Beam Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-004858

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.